Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ObsEva SA

www.obseva.com

Latest From Mediolanum Farmaceutici SRL

Deals Shaping the Medical Industry, December 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2016.

Deals BioPharmaceutical

DEALS ROUND-UP: M&A and partnering 1-28 December

As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.

Metabolic Disorders Infectious Diseases

Deals Of The Week: Baxter/Gambro, Optimer/AstraZeneca, Ironwood/Protagonist

Three rapid-fire clinical setbacks scuttled a planned merger between BioCryst and Presidio that would have created a new competitor in the hepatitis C space. Now, BioCryst is retrenching with a staff cut and narrower R&D focus.

BioPharmaceutical Deals

Mediolanum Acquires Phase II-Ready Cancer Vaccine From Italy’s Genovax

Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its first transaction, selling Genovax’s potential cancer vaccine to Italian pharmaceutical company Mediolanum.

BioPharmaceutical Italy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • ObsEva SA
  • Senior Management
  • Ernest Loumaye, MD, PhD, CEO
    Timothy Adams, CFO
    Jean-Pierre Gotteland , PhD, CSO
    Ben Tang, VP, Commercial & Bus. Dev.
  • Contact Info
  • ObsEva SA
    Chemin des Aulx 12
    Plan-les-Ouates, 1228
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register